We now offer SARS-CoV-2 (COVID-19) testing by RT-qPCR and COVID-19 (SARS-CoV-2) IgM/IgG antibody testing

Learn more about our tests

• Notice on Mandatory COVID-19 Negative Certificates for China-bound Passengers Before Boarding
• Letter of authorization for Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit
• Notice about false positive results for COVID-19 IgM/IgG Antibody Testing

To order a COVID-19 test:

1. Please make sure that saliva is an acceptable sample source.
2. To obtain a doctor prescription: Please complete the Requisition Form for COVID-19 Diagnostic Testing.  Please email the completed form to inquiry@mvisionlab.com. We will forward the form to a doctor working with us for approval. Please note that the doctor consultation and diagnostic test are separate charges.
3. Once your payment has processed, you will receive instructions by email to schedule a supervised saliva collection at our facility.
4. The diagnostic test costs $99 for a next day turnaround time of ~26 hours or $150 for a same day turnaround time of ~6 hours. The antibody test costs $50.  Please note that there is an additional fee of $35 (paid directly to the doctor) to obtain a doctor’s prescription through us. We will provide you instructions on how to complete the doctor’s fee when you provide your sample.

Download Requisition Form

About our tests

Molecular Vision Laboratory (MVL) is a CAP and CLIA-certified molecular diagnostic laboratory that provides state-of-the-art genetic testing for clients worldwide. We are a genetic testing reference laboratory for clinical trials of several inherited retinal dystrophies. We perform high complexity testing routinely and we are well-equipped with latest technologies including Next Generation Sequencing and quantitative PCR.

We now offer NP swab testing of SARS-CoV-2 (COVID-19) by RT-qPCR. MVL SARS-CoV-2 (COVID-19) RT-qPCR is a Lab Developed Test (LDT) based on Thermo Fisher Scientific platforms (RNA isolation and RT-qPCR). Samples must be collected and submitted by or under supervision of a health care provider.

Results are for the identification of SARS-CoV-2 (COVID-19) RNA. The SARS-CoV-2 (COVID-19) RNA is generally detectable in upper respiratory and bronchoalveolar lavage (BAL) specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 (COVID-19) RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 (COVID-19) infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

DISCLAIMER: This test was developed, and its performance characteristics determined by Molecular Vision Lab. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Sample collection step is the most critical step for the performance of the test. False negative result may occur due to sub-optimal collections of saliva samples. Additionally, various infection stages may produce different number of viruses in collections. A negative result only suggests no detectable viruses are present by the method and/or at the current stage of infection. Repeating testing at a different stage of infection may be necessary.